SBHMY vs DOCU
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
SBHMY · SINO BIOPHARMACEUT$14.62 ▲ 3.15%
DOCU · DocuSign$77.61 ▼ 1.66%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- SBHMY -23.0%
- DOCU +11.4%
Head to head
| Metric | SBHMY | DOCU |
|---|---|---|
| Price | $14.62 | $77.61 |
| Change today | ▲ 3.15% | ▼ 1.66% |
| Market cap | $14.50B | $14.51B |
| Return, 3 months | +13.9% | +30.1% |
| Return, year to date | -17.8% | +13.5% |
| Return, 1 year | -23.0% | +11.3% |
| P/E (TTM) | 38.5 | 47.3 |
| P/B | 2.7 | 8.4 |
| P/E percentile vs own 5y | – | 77th |
| Dividend yield | 2.09% | – |
| Revenue growth (YoY, latest qtr) | – | +9.4% |
| Net profit growth (YoY) | – | +23.4% |
| Gross margin | – | 79.5% |
| Operating margin | – | 12.0% |
| Net margin | – | 9.8% |
| Return on equity | – | 17.8% |
| Analyst target vs. price | – | -6.8% |
| Analyst buy share | – | 18% |
| RSI (14) | 57 | 51 |
| 30-day volatility | 96.1% | 36.3% |
| Max drawdown, 1 year | -42.0% | -42.9% |
| Trend read | Strong uptrend | Leaning bullish |
| Analyst consensus | – | Hold |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- DOCU is the largest of the group by market value.
- DOCU has returned the most over the past year.
- SBHMY carries the lowest trailing P/E.
- DOCU has been the calmest stock over the last 30 days.